title: Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen.
abstract: Prednisone treatment delays the progressive course of Duchenne muscular dystrophy. The aim of this study was to determine the influence of the 10 day on/10 day off treatment on height and weight. We retrospectively reviewed the growth and weight charts of Duchenne patients born between 1988 and 2006 (patients between 4 and 9 years old, being able to walk in the home situation). Forty-seven patients were eligible for further analysis and divided into two groups: 33 patients treated with prednisone and 14 non-prednisone treated patients. Results of a median follow-up of 57 months (range 27-146) are described. By using linear mixed models this study demonstrates that height and body mass index in prednisone-treated patients with 10/10 regimen are not significantly different compared to untreated patients. We cautiously conclude that the alternating prednisone regimen has no apparent side effects on weight and height in the ambulatory phase of Duchenne muscular dystrophy.
authors.affiliation: Department of Pediatric Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen-Medical Centre, The Netherlands.
authors.forename: K
authors.initials: K
authors.lastname: ten Dam
authors.forename: I J M
authors.initials: IJ
authors.lastname: de Groot
authors.forename: C
authors.initials: C
authors.lastname: Noordam
authors.forename: N
authors.initials: N
authors.lastname: van Alfen
authors.forename: J C M
authors.initials: JC
authors.lastname: Hendriks
authors.forename: L T L
authors.initials: LT
authors.lastname: Sie
mesh_terms: D001827:Body Height / Q000187:drug effects* / Q000502:physiology; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy* / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D011241:Prednisone